While the need for prospective trials dominates the ctDNA discussion, a more fundamental obstacle is the lack of standardization between assay types (e.g., tumor-informed vs. agnostic). Without a common measurement approach, data from disparate trials cannot be pooled to create a universally accepted surrogate endpoint for regulatory approval.

To reduce treatment delays, pathologists should initiate biomarker testing reflexively. Waiting for a medical oncologist to order tests at a first visit is a system failure, wasting critical time and risking the need to retrieve archived samples.

Dr. Deb Schrag suggests the main challenge for new molecular cancer screening technologies is not invention, but implementation. The critical task will be deploying these tools at a population scale and effectively managing the logistical challenge of distinguishing true positives from false alarms.

Advancing circulating tumor DNA (ctDNA) as a surrogate endpoint is stalled because the necessary large-scale, prospective validation studies are too expensive for any single company. The path forward requires a massive public-private partnership to fund research and establish standards, otherwise progress will remain incremental.

Despite significant academic interest, the KIM1 plasma biomarker is far from clinical implementation. Key hurdles include the lack of a commercially available, standardized assay and prospectively validated cutoff points. It remains an experimental tool with high variability and unproven utility.

To ensure patients get the same result from any test provider, the field must standardize not just the underlying sequencing technology, but also the software pipelines for data analysis and the clinical frameworks for interpreting results. Each layer presents a unique harmonization challenge.

Clinicians ordering "NGS for lung" often misunderstand that Next-Generation Sequencing alone does not cover all actionable biomarkers, such as PD-L1 or HER2. This requires pathologists to interpret the clinician's intent and order a more comprehensive and appropriate test panel.

Data shows an average two-week delay occurs between a lung cancer patient's biopsy and the ordering of essential biomarker tests. This administrative gap, separate from the diagnostic process itself, is a major bottleneck that postpones critical treatment decisions.

The main barrier to widespread ctDNA use is not its proven ability to predict who will recur (prognostic value). The challenge is the emerging, but not yet definitive, data on its ability to predict a patient's response to a specific therapy (predictive value).